Diabetic Retinopatathy
|
|
- Reynold Short
- 6 years ago
- Views:
Transcription
1 Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced Ocular Care Genentech USA USMA Lampa Advisory Executive Clinical Director Retina and Macula Specialists Jan. 28, The number of older Americans diagnosed with diabetes grew by nearly a quarter in the last decade, a rate that experts say threatens not only the health of the elderly but the viability of the nation's health care system. Type 2 diabetes is the most prevalent form of the disease, accounting for 90 to 95% of all diabetes cases in America AND is largely preventable according to the CDC. Although the vast majority of individuals with type 2 diabetes are adults, children and adolescents are increasingly at risk for the disease due to growing childhood weight problems and sedentary lifestyles. 1
2 Research suggests that 1 out of 3 adults has prediabetes. Of this group, 9 out of 10 don't know they have it million people in the United States have diabetes, but 8.1 million may be undiagnosed and unaware of their condition. About 1.4 million new cases of diabetes are diagnosed in United States every year. More than one in every 10 adults who are 20 years or older has diabetes. For seniors (65 years and older), that figure rises to more than one in four. Cases of diagnosed diabetes cost the United States an estimated $245 billion in This cost is expected to rise with the increasing diagnoses. The International Diabetes Federation reports that more than 400 million people were living with diabetes as of Prior estimations predicted 300 million by Either you have it or you don t. That's the message that the American Diabetes Association (ADA) is driving home to millions of people who believe they may be "borderline diabetic," or that their "sugar is just a bit high." What is diabetes? DM is a chronic disorder characterized by a lack of insulin or increased resistance to insulin Insulin is needed for proper uptake of glucose Clinical result is hyperglycemia retinopathy nephropathy neuropathy Diabetes: Magnitude of Complications Leading cause of blindness in working age adults Diabetic Retinopathy Stroke 2- to 4- fold increase in cardiovascular mortality and stroke Obesity Trends* Among U.S. Adults BRFSS, 1994 (*BMI 30, or ~ 30 lbs overweight for 5 4 person) Diabetic Nephropathy Leading cause of end-stage renal disease Cardiovascular Disease Diabetic Neuropathy Leading cause of non-traumatic lower extremity amputations No Data <10% 10% 14% 15% 19% 20% 24% 25% 2
3 New Diagnosis Criteria Panel of experts at ADA annual meeting are recommending A1C be used for diagnosis of diabetes Glycosolated hemoglobin Tells blood sugar control over 3 months normal range 4% to 6% What do the results of the Hemoglobin A1c mean.? HgbA1c BS Level HgbA1c BS Level What do the results of the Hemoglobin A1c mean.? What is our role?? 3
4 - Classification of : Non Proliferative Mild Moderate Severe Very Severe Proliferative - Classification of : H/MA hemorrhage or microaneurysm VB venous beading IRMA intraretinal microvascular abnormalities NEO - neovascularization - Classification of : Mild Non Proliferative At least one microaneurysm Characteristics not met for more severe retinopathy - Classification of : Moderate Non Proliferative H/MA greater than standard photograph No. 2A and/or Cotton wool spots, VB, or IRMA present OCT Angiography (OCTA) Characteristics not met for more severe retinopathy 4
5 - Classification of : Severe Non Proliferative H/MA greater than standard photograph No. 2A in 4 quadrants or VB in 2 or more quadrants or IRMA greater than standard photograph No. 8A in at least 1 quadrant RULE Characteristics not met for more severe retinopathy - Classification of : Very Severe Non Proliferative Two or more criteria of Severe NPDR No frank neovascularization - Classification of : H/MA s in 4 quadrants = Severe Non PDR 5
6 - Classification of : - Classification of : IRMA in 2 quadrants = Severe Non PDR H/MA s in 4 quadrants = Severe Non PDR IRMA in 2 quadrants = Severe Non PDR Rate of Progression to PDR 1 year 3 years Mild NPDR 5 % 14% Moderate NPDR Severe NPDR Classification of : Proliferative Neovascularization of the disc (NVD) < Standard photo 10A (< disc area) Neovascularization elsewhere in the retina (NVE) without associated vitreous or pre-retinal hemorrhage Treatment: Clinically Significant Macular Edema Laser Photocoagulation is recommended for patients who meet criteria for CSME regardless of visual acuity. Laser Photocoagulation reduces the risk for moderate vision loss by 50%. Moderate vision loss is doubling the visual angle. 6
7 Treatment: Clinically Significant Macular Edema Despite the guidelines for treatment of CSME with laser photocoagulation, many patients are treated with intravitreal agents such as Avastin, Lucentis, Triesence and Eylea initially. Diabetic Macular Edema: Approved Pharmacologic Treatment Lucentis (Ranibizumab) Eylea (Aflibercept) Diabetic Macular Edema: Approved Pharmacologic Treatment Ozurdex (Dexamethasone Intravitreal Implant) Diabetic Macular Edema: FUTURE: Pharmacologic Treatment Iluvien (Fluocinolone Acetonide Implant) 36 month duration 80 % cataract 35% elevated IOP greater than 10mmHg (5% require glaucoma surgery) Treatment: Diabetic Macular Edema (antivegf) Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema (Protocol T) 7
8 Protocol T Ranibizimab was the first approved anti VEGF treatment option for diabetic macular edema (DME) and studies have shown it to be safe and efficacious and superior to focal/grid laser alone for patients with center involved DME. A concern is the cost per dose of ranibizumab and the need for multiple treatments over time. Protocol T Is there an alternative anti VEGF agent that might prove to be as efficacious, deliver equal or longer acting effects and cost substantially less. Bevacizumab and Afliberacept are the other options available for comparison. 660 adults in 89 clinical sites Protocol T - Ranibizumab 0.3 mg every 4weeks at baseline and up to every 4 weeks using defined re treatment criteria - Bevacizumab 1.25 mg every 4weeks at baseline and up to every 4 weeks using defined re treatment criteria - Afliberacept 2.0 mg every 4weeks at baseline and up to every 4 weeks using defined re treatment criteria Protocol T Primary Outcome Measures: Overall change in visual acuity measured at 1 year Change in VA measured from baseline to 1 year Baseline VA letter score <69 (20/50 or worse) Change in VA measured from baseline to 1 year Baseline VA letter score (20/30 20/40) Protocol T Secondary Outcome Measures: (at 1 year) Overall change in OCT central subfield thickness Change in OCT central subfield thickness from baseline to 1 year Baseline VA letter score <69 Change in OCT central subfield thickness from baseline to 1 year Baseline VA letter score Protocol T Secondary Outcome Measures: Overall change in retinal volume Total number of injections prior to one year Total number of laser treatments Eyes receiving 1 or more alternative treatments for DME other than laser 8
9 MEAN CHANGE IN VISUAL ACUITY LETTER SCORE MEAN CHANGE IN VISUAL ACUITY LETTER SCORE MEAN CHANGE IN VISUAL ACUITY LETTER SCORE MEAN CHANGE IN VISUAL ACUITY LETTER SCORE Protocol T 20 Mean Change in Visual Acuity Letter Score Baseline Visual Acuity 20/32 to 20/40 Results: Year 1 all three anti VEGF compounds improved acuity, on average, in patients with baseline acuity of 20/40 to 20/32 but Afliberacept was superior when baseline acuity was 20/50 or worse ~50% of Cohort ~ WEEKS Aflibercept Bevacizumab Ranibizumab Mean Change in Visual Acuity Letter Score Baseline Visual Acuity 20/50 or Worse +19 Protocol T ~ 50% of Cohort +14 Results: WEEKS Aflibercept Bevacizumab Ranibizumab Year 2 improved vision was again noted in all 3 groups with an average of half of the number of injections, decreased frequency of visits and a decrease in the need for focal/grid laser treatment. * P-values adjusted for baseline visual acuity and multiple comparisons Mean Change in Visual Acuity Over 2 Years Full Cohort Mean Change in Visual Acuity Over 2 Years Baseline Visual Acuity 20/50 or Worse ~50% of Cohort WEEKS Aflibercept Bevacizumab Ranibizumab * P-values adjusted for baseline visual acuity and multiple comparisons * P-values adjusted for baseline visual acuity and multiple comparisons WEEKS Aflibercept Bevacizumab Ranibizumab 9
10 New description Diabetic Macular Edema: Diabetic Macular Edema: Clinical Trials Center Involved Macular Edema CSME has now been further characterized Center involved edema Non center involved edema Diabetic Macular Edema: Clinical Trials Non - Center Involved Macular Edema Treatment: Proliferative The Study showed that scatter laser PRP reduced the incidence of severe vision loss by up to 50 % in patients with Proliferative. Severe vision loss is < 5/200 Treatment: Proliferative Treatment: Proliferative 10
11 Treatment: Proliferative Proliferative - OCTA INSERT CLARUS IMAGE HERE OF PRP 55 year old man with Type I Diabetes 55 year old man with Type I Diabetes AngioPlex VRI slice confirms neovascularization (NVE) AngioPlex / FA images showing neovascularization (NVE) as well as the enlarged FAZ Proliferative - OCTA Even with treatment and resolution of macular edema some patients continue to have severe vision loss.. Driven by ischemia! 11
12 OCT angiography Zeiss AngioPlex Combination therapy has become standard for the treatment of diabetic retinopathy. Prolferative Retinopathy with marked non perfusion and NVE 1 Month status post AVASTIN with panretinal laser treatment. 3 Months status post AVASTIN with panretinal laser treatment. Vitreous Hemorrhage and Traction Retinal Detachments Despite best efforts to manage complications of diabetes in the office some patients require surgical intervention with Vitrectomy. 12
13 Vitreous Hemorrhage and Traction Retinal Detachments Traction Retinal Detachment 1 month s/p silicone oil Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (Protocol S) Ptotocol S Randomized Clinical Trial evaluated noninferiority of ranibizumab vs. panretinal photocoagulation (PRP) with a primary endpoint of mean change in visual acuity from baseline to 2 years. 203 eyes randomized to receive PRP 191 eyes received 0.5mg intravitreous ranibizumab at baseline and every 4 weeks based on re treatment protocol 13
14 Protocol S 2 Year results: Visual acuity improvement PRP group improvement in 0.2 letters 0.5 mg ranibizumab group 2.8 letters Protocol S 2 Year results: Peripheral VF loss and Vitrectomy PRP group 531 db loss and 15% needed surgery 0.5 mg ranibizumab group 213 db loss and 4 % Ranibizumab Approved in 2017 to treat ALL levels of Diabetic Retinopathy Type I Diabetes with Proliferative Retinopathy PRP laser treatment in 1990 Will this change what we do for patients with a chronic diabetic eye disease? Is it the right thing to do? Type I Diabetes with Proliferative Retinopathy PRP laser treatment in OCTA Type I Diabetes with Proliferative Retinopathy PRP laser treatment in OCTA 14
15 Type I Diabetes with Proliferative Retinopathy PRP laser treatment in OCTA Although clinical trials have defined the standard of care for management of CSME and PDR..intravitreal agents like Avastin/Lucentis, Eylea and Steroids have rapidly become adjuncts to laser treatment and prior to Vitrectomy surgery. Avastin has also become a crucial component in the management of neovascular glaucoma by inducing regression of rubeosis within a few days. Referral Criteria: Non Proliferative Mild NPDR follow yearly Moderate NPDR follow q6 12 months Severe NPDR follow q4-6 months / REFER? Very Severe NPDR follow q3 months / REFER? ** Consider patient control of diabetes ** Consider success of therapy ** Consider risks for progression to PDR ** Consider personal comfort level Referral Criteria: Proliferative - Prompt referral for pan retinal photocoagulation based of the guidelines of the DRS. - If rubeosis is present Avastin + PRP should be initiated within hours to prevent neovascular glaucoma. Referral Criteria: Diabetic Macular Edema Referral Criteria: Diabetic Macular Edema - Follow the guidelines of the ETDRS when considering the referral?? - Most retina surgeons will treat center involved diabetic macular edema Center versus non center involved edema.. 15
16 16
Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington
Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington I Jay M. Haynie, OD, FAAO have received honoraria from the following companies: Reichert Technologies Notal Vision Carl Zeiss Meditec
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationMarcus Gonzales, OD, FAAO Cedar Springs Eye Clinic
Marcus Gonzales, OD, FAAO Cedar Springs Eye Clinic 25.6 million adults 11.3% of the adult population 10.9 million adults 65 years and older 26.9% of this age population 79 million people are Pre-diabetic!!
More informationDiabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina
Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.
More informationEyes on Diabetics: How to Avoid Blindness in Diabetic Patient
Eyes on Diabetics: How to Avoid Blindness in Diabetic Patient Rova Virgana FK Unpad Pusat Mata Nasional RS Mata Cicendo Bandung Eye Center (Hospital and Clinic) PIT IDI Jabar 2018 Keys Facts from WHO
More informationPast ocular history. DME Case 1. Patient presents blurred VA. Hemoglobin A1c 11.5% -- patient states sugars have not been in good control
Past ocular history Patient presents blurred VA DME Case 1 Hemoglobin A1c 11.5% -- patient states sugars have not been in good control PDR with macular edema OU Rishi Singh MD Cleveland Clinic OD OS 1
More informationDiabesity A Public Health Crisis: AOA Evidence Based Translation to Care Series
Diabesity A Public Health Crisis: AOA Evidence Based Translation to Care Series Joseph J. Pizzimenti, OD, FAAO Associate Professor Nova Southeastern University The Eye Care Institute pizzimen@nova.edu
More informationFacts About Diabetic Eye Disease
Facts About Diabetic Eye Disease Points to Remember 1. Diabetic eye disease comprises a group of eye conditions that affect people with diabetes. These conditions include diabetic retinopathy, diabetic
More informationDiabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012
Diabetic Retinopathy Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Outline Statistics Anatomy Categories Assessment Management Risk factors What do you need to do? Objectives Summarize the
More informationRetinal Complications of Obstructive Sleep Apnea A Growing Concern!
Retinal Complications of Obstructive Sleep Apnea A Growing Concern! Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl
More informationThe Diabetic Retinopathy Clinical Research Network. Management of DME in Eyes with PDR
The Diabetic Retinopathy Clinical Research Network Management of DME in Eyes with PDR 1 What Has Been Learned? Diabetic Retinopathy Treatment Protocol F: Results suggest that clinically meaningful differences
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationEyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy. George Bresnick MD MPA Jorge Cuadros OD PhD
EyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy George Bresnick MD MPA Jorge Cuadros OD PhD Anatomy of the eye: 3 Normal Retina Retinal Arcades Macula Optic
More informationPART 1: GENERAL RETINAL ANATOMY
PART 1: GENERAL RETINAL ANATOMY General Anatomy At Ora Serrata At Optic Nerve Head Fundoscopic View Of Normal Retina What Is So Special About Diabetic Retinopathy? The WHO definition of blindness is
More informationmeasure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control
More informationDIABETIC RETINOPATHY
DIABETIC RETINOPATHY C. L. B. Canny, MD FRCSC Diabetic retinopathy is the most serious eye manifestation of diabetes and is responsible for most of the blindness caused by diabetes. Diabetic retinopathy
More informationNew Developments in the treatment of Diabetic Retinopathy
New Developments in the treatment of Diabetic Retinopathy B. Jeroen Klevering University Medical Centre Nijmegen - The Netherlands Topics Management of diabetic retinopathy Interventions a. primary (prevention)
More informationOCT Interpretation in Retinal Disease
OCT Interpretation in Retinal Disease Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Advanced Ocular
More information1/25/2018. Case Management Strategies in Diabetic Retinopathy. Case Study #1: Severe DME. DDOS: 3/31/2016 Va 20/400. Disclosures
Case Management Strategies in Diabetic Retinopathy Disclosures No financial conflict of interest Will discuss off label use of intraocular Bevacizumab (Avastin) for Diabetic Retinopathy Sundeep Dev, MD
More informationFRANZCO, MD, MBBS. Royal Darwin Hospital
Diabetes and Eye By Dr. Nishantha Wijesinghe FRANZCO, MD, MBBS Consultant Ophthalmologist Royal Darwin Hospital 98% of Diabetics do not need to suffer from severe visual loss Yet Diabetic eye disease is
More informationScott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012
Scott M. Pfahler D.O. Dayton Vitreo-Retinal Associates AOCOO-HNS Palm Springs, CA 2012 Proliferative Diabetic Retinopathy Laser Treatments Medical Treatment Surgical Treatment Diabetic Macular Edema Laser
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes can be classified into type 1 diabetes mellitus and type 2 diabetes mellitus, formerly known as insulin-dependent diabetes mellitus, and non-insulin diabetes mellitus, respectively.
More informationDiabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches
Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada
More informationClinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.
1 Clinical Trials in Diabetic Retinopathy 2018 Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D. Bascom Palmer Eye Institute 900 N.W. 17th Street Miami, FL 33136 Phone: (305) 326-6118 Fax: (305) 326-6417
More informationDIABETES AND YOUR EYES. Presented by Dr. Andrea Hagler
DIABETES AND YOUR EYES Presented by Dr. Andrea Hagler Tahlequah, OK Forest Grove, OR Brief Review of Diabetes The body s endocrine system is responsible for regulating growth, reproduction, and tissue
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May
BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of
More informationRetinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)
Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England (Royal Victoria Infirmary, Sunderland Eye Infirmary, James Cook University Hospital, Darlington Memorial Hospital, University Hospital
More informationSerious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist
Serious Eye diseases, New treatments Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist 5 major causes of loss of vision Cataracts Glaucoma Macular degeneration Retinal Vein occlusions
More informationFROM OUTDATED TO UPDATED Eminence-Based Medicine
FROM OUTDATED TO UPDATED Eminence-Based Medicine Evidence-Based Medicine A REVIEW OF KEY CLINICAL TRIALS Anthony DeWilde, OD FAAO 1 EMINENCE BASED MEDICINE 2 EVIDENCE BASED MEDICINE 3 4 CLINICAL TRIALS
More informationMedical Retina 2011 Nicholas Lee
Medical Retina 2011 Nicholas Lee 1 Diabetic Retinopathy Epidemiology 1000 registered blind each year 2% diabetics registered as blind (8% of all Blind Registrations) 42% with Mild Background DR will progress
More informationBrampton Hurontario Street Brampton, ON L6Y 0P6
Diabetic Retinopathy What is Diabetic Retinopathy Diabetic retinopathy is one of the leading causes of blindness world-wide. Diabetes damages blood vessels in many organs of the body including the eyes.
More information10/8/13. the diabetes epidemic: strategies for saving sight. financial disclo$ure. unlabeled-investigative use disclosure
10/8/13 ASORN 2013 Annual Meeting New Orleans, LA the diabetes epidemic: strategies for saving sight Kate Goldblum, CNP financial disclo$ure I have no financial interests relevant to my presentation. unlabeled-investigative
More informationOutline. Preventing & Treating Diabetes Related Blindness. Eye Care Center Doctors. Justin Kanoff, MD. Eye Care Center of Northern Colorado
Outline Preventing & Treating Diabetes Related Blindness Justin Kanoff, MD Eye Care Center of Northern Colorado 303 974 4302 Introduction to Eye Care Center of Northern Colorado How the eye works Eye problems
More informationA Patient s Guide to Diabetic Retinopathy
Diabetic Retinopathy A Patient s Guide to Diabetic Retinopathy 840 Walnut Street, Philadelphia PA 19107 www.willseye.org Diabetic Retinopathy 1. Definition Diabetic retinopathy is a complication of diabetes
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes mellitus is one of the leading causes of irreversible blindness worldwide. In the United States, it is the most common cause of blindness in people younger than 65 years.
More informationWhat is diabetes? Ocolusystemic Disease Essen6als. Statistics, cont. Statistics. Statistics. The Diabetes Epidemic 9/5/12
What is diabetes? Ocolusystemic Disease Essen6als Steven Ferrucci, OD, FAAO Chief, Optometry Sepulveda VA Associate Professor, SCCO DM is a chronic disorder characterized by a lack of insulin or increased
More informationDiabetic and the Eye: An Introduction
Diabetic and the Eye: An Introduction Lawrence Iu FRCSEd (Ophth), FCOphthHK, FHKAM (Ophthalmology) Department of Ophthalmology, Grantham Hospital & Queen Mary Hospital Background Diabetes mellitus (DM)
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk Version 4.0 September 19, 2017 Anti-VEGF
More informationParadigm Shift in the treatment of Diabetic Retinopathy. Haytham I. S. Salti, MD Associate Professor
Paradigm Shift in the treatment of Diabetic Retinopathy Haytham I. S. Salti, MD Associate Professor Disclosure No financial interests related to the subject matter of this talk This presentation includes
More informationDiabetic maculopathy 11/ An update on. Miss Vasuki Sivagnanavel
Miss Vasuki Sivagnanavel Consultant Ophthalmologist An update on Diabetic maculopathy Despite advances in the management of diabetes, diabetic retinopathy is already the commonest cause of blindness among
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationDiabetic Macular Edema Treatment in the 21st Century
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationVascular Disease Ocular Manifestations of Systemic Hypertension
Vascular Disease Ocular Manifestations of Systemic Hypertension Maynard L. Pohl, OD, FAAO Pacific Cataract & Laser Institute 10500 NE 8 th Street, Suite 1650 Bellevue, WA 98004 USA 425-462-7664 Cerebrovascular
More informationMeasures have been taken, by the Utah Department of Health, Bureau of Health Promotions, to ensure no conflict of interest in this activity.
Measures have been taken, by the Utah Department of Health, Bureau of Health Promotions, to ensure no conflict of interest in this activity. CNE/CPE/CEU s are available for this live webinar. You must
More informationThe Human Eye. Cornea Iris. Pupil. Lens. Retina
The Retina Thin layer of light-sensitive tissue at the back of the eye (the film of the camera). Light rays are focused on the retina then transmitted to the brain. The macula is the very small area in
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (Protocol
More informationPreventing Avoidable Vision loss from Diabetic Retinopathy in Indian Country
Diabetes in Indian Country- 2017 Preventing Avoidable Vision loss from Diabetic Retinopathy in Indian Country Albuquerque, NM 20 September2017 Mark B. Horton, OD, MD Director, IHS/JVN Teleophthalmology
More informationDIABETIC RETINOPATHY (DR) PREFERRED PRACTICE PATTERNS (PPP) Philippines 2016
DIABETIC RETINOPATHY (DR) PREFERRED PRACTICE PATTERNS (PPP) Philippines 2016 The Diabetic Retinopathy (DR) Preferred Practice Patterns (PPP) Philippines: 2016 was prepared by the VitreoRetina Society of
More information8/8/17. Objectives. Proliferative Diabetic Retinopathy (PDR) Examining the Diabetic Patient: What Matters Most
Objectives Examining the Diabetic Patient: What Matters Most Jordan Keith, OD, FAAO Minneapolis, MN Simplify strategy for evaluating the eyes of diabetics Identify the threats to vision and treatments
More informationDiabetic Retinopathy A Presentation for the Public
Diabetic Retinopathy A Presentation for the Public Ray M. Balyeat, MD The Eye Institute Tulsa, Oklahoma The Healthy Eye Light rays enter the eye through the cornea, pupil and lens. These light rays are
More informationZEISS AngioPlex OCT Angiography. Clinical Case Reports
Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy
More informationVenous Occlusive Diseases
Venous Occlusive Diseases Bruce R. Saran, MD Adjunct Assistant Clinical Professor of Medicine Scheie Eye Institute University of Pennsylvania School of Medicine Philadelphia, PA -a division of: RVO Demographics
More informationFront Line Diabetic Retinopathy What Not to Miss and Why
Front Line Diabetic Retinopathy What Not to Miss and Why David M Brown MD FACS Clinical Professor of Ophthalmology Blanton Eye Institute, Houston Methodist Hospital Baylor College of Medicine Retina Consultants
More informationPersistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment
9:30 AM Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment Lee Jampol, MD OBJECTIVE To assess subsequent visual and anatomic outcomes of eyes with
More informationINTRODUCTION AND SYMPTOMS
CHAPTER 1 INTRODUCTION AND SYMPTOMS Introduction of Diabetic Retinopathy Diabetic retinopathy (DR) is a potentially blinding complication of diabetes. It is defined as presence of one or more definite
More informationILUVIEN IN DIABETIC MACULAR ODEMA
1 ILUVIEN IN DIABETIC MACULAR ODEMA Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars conference 2104 1 2 Declaration of interest I have sat on Advisory boards for
More informationDiabetic Retinopathy Update 2017
Diabetic Retinopathy Update 2017 Basis for DR management standards for past 40 years Diabetic Retinopathy Study (DRS) 1971-1989 and Early Treatment of Diabetic Retinopathy Study (ETDRS) 1979-1990 Sundeep
More informationEpidemiology and Pathophysiology of Diabetic Retinopathy
Epidemiology and Pathophysiology of Diabetic Retinopathy Vincent Reppucci, MD Director, Retina Service Mt. Sinai St. Luke s-roosevelt Hospital Attending Physician, Retina Service New York Eye and Ear Infirmary
More informationDiabetic Management beyond traditional risk factors and LDL-C control: Can we improve macro and microvascular risks?
Retinopathy Diabetes has a negative effect on eyes in many ways, increasing the risk of cataracts for example, but the most common and serious ocular complication of diabetes is retinopathy. Diabetic retinopathy
More informationDiabetic Retinopathy
Diabetic Retinopathy Overview This presentation covers the following topics: Definitions Epidemiology of diabetic retinopathy Evidence for public health approaches Screening for diabetic retinopathy Health
More informationDiabetic Retinopathy What You Should Know. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute
Diabetic Retinopathy What You Should Know U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute The National Eye Institute (NEI) conducts and supports research
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Aflibercept for treating diabetic macular oedema Final scope Final remit/appraisal objective To appraise the clinical and cost
More informationThe Era of anti- - - VEGF Kirk L. Halvorson, OD
The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Version
More informationEU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO
EU Regulatory workshop Ophthalmology clinical development and scientific advice. Industry view on DME and macular edema secondary to RVO Yehia Hashad, M.D. Vice President and Global Therapeutic Area Head
More informationDiabetes and Eye Health more than meets the eye Vision Initiative - in association with PSA
Diabetes and Eye Health more than meets the eye Vision Initiative - in association with PSA Vision 2020 Australia Vision Initiative RANZCO & OAA (Vic) Proud members of Vision 2020 Australia Outline Vision
More informationRetinal Vein Occlusion
Retinal Update 2018 Retinal Vein Occlusion Case Presentations to Myself Branch Vein Occlusion What medical evaluation do you recommend for this 72 year old patient? Is there anything you ask of your medical
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Version
More informationDiabetic eye disease. Diabetic retinopathy. Sam S. Dahr, M.D. Retina Center of Oklahoma.
Diabetic eye disease Sam S. Dahr, M.D. Retina Center of Oklahoma www.rcoklahoma.com Downloaded from: The Retina (on 28 May 2007 12:48 AM) 2007 Elsevier Diabetic retinopathy Downloaded from: The Retina
More informationAn Update on Branch Retinal Vein Occlusion Treatment Studies. Amiee Ho, O.D. Pacific University College of Optometry
An Update on Branch Retinal Vein Occlusion Treatment Studies Amiee Ho, O.D. Pacific University College of Optometry Course Description This course focuses on current treatment options available for macular
More informationRANZCO Screening and Referral Pathway for Diabetic Retinopathy #
RANZCO Screening and Referral Pathway for Diabetic Retinopathy # Patient Presents a. Screen for Diabetic Retinopathy every 2 years b. Begin screening at diagnosis of Diabetes * Clinical Modifi ers Yearly
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationCURRENT TRENDS IN DIABETIC MACULAR EDEMA TREATMENT. Muge R. Kesen, MD
CURRENT TRENDS IN DIABETIC MACULAR EDEMA TREATMENT Muge R. Kesen, MD No relevant financial interest or relationships DISCLOSURE OBJECTIVES Current trends (evidence based) Review of clinical trials Diabetic
More informationRecalcitrant Diabetic Macular Oedema: Therapeutic Options
December 2007 A. Giridhar et al. - Recalcitrant DME 451 CONSULTATION S E C T I O N Recalcitrant Diabetic Macular Oedema: Therapeutic Options Dr. Cyrus M Shroff 1, Dr. N S Muralidhar 2, Dr. R Narayanan
More informationThe Posterior Segment in Diabetes
The Posterior Segment in Diabetes Course Goal! To provide useful clinical information about current standards in the treatment and management of diabetes and diabetic retinopathy. Carlo J. Pelino, OD,
More informationDiabetic Retinopathy Screening in Hong Kong. Dr. Rita Gangwani M.S, FRCS (Ophth), FCOphth(HK), FHKAM Eye Institute, The University of Hong Kong
Diabetic Retinopathy Screening in Hong Kong Dr. Rita Gangwani M.S, FRCS (Ophth), FCOphth(HK), FHKAM Eye Institute, The University of Hong Kong Co-Investigators Prof. David Wong Prof. Sarah McGhee Dr. Wico
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Short-term Evaluation of Combination Corticosteroid+Anti- VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy
More informationCase Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema V Swetha E Jeganathan 1,2 * and Karen Madill 3 1 Department of Ophthalmology,
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab,
More informationIs OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema
Is OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema Ayman M Khattab MD, FRCS Professor of Ophthalmology Cairo University Diabetic Macular Edema (DME) Diabetic macular
More informationDiabetic retinopathy (DR) is the leading PROCEEDINGS EVIDENCE-BASED DATA IN THE TREATMENT OF DIABETIC RETINOPATHY*
EVIDENCE-BASED DATA IN THE TREATMENT OF DIABETIC RETINOPATHY* Lloyd Paul Aiello, MD, PhD, and Jennifer K. Sun, MD, MPH ABSTRACT There is a wide array of research into the pathophysiology and treatment
More informationTreatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity
Diabetic Retinopathy Clinical Research Network Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity Version 3.0 April 18, 2014 Treatment of CIDME in Eyes with Good
More informationEyePACS Grading System (Part 2): Detecting Presence and Severity of Background (Non-Proliferative) Diabetic Retinopathy Lesion
EyePACS Grading System (Part 2): Detecting Presence and Severity of Background (Non-Proliferative) Diabetic Retinopathy Lesion George Bresnick MD MPA Jorge Cuadros OD PhD Anatomy of the eye: 3 Normal Retina
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationDiabetes & Your Eyes
Diabetes & Your Eyes Diabetes is a disease that occurs when the pancreas does not secrete enough insulin or the body is unable to process it properly. Insulin is the hormone that regulates the level of
More informationDiabetic Retinopathy
Diabetic Retinopathy Secretary for Quality of Care Anne L. Coleman, MD, PhD Academy Staff Nicholas P. Emptage, MAE Doris Mizuiri Shannon Kealey, MLS Flora C. Lum, MD Medical Editor: Design: Approved by:
More informationA Systematic Approach to Diabetic Photo Reading
A Systematic Approach to Diabetic Photo Reading Jacqueline Theis, OD, FAAO Please silence all mobile devices and remove items from chairs so others can sit. Unauthorized recording of this session is prohibited.
More informationPrevalence of Diabetes Mellitus Affects 9.3% of the US popularon (29.1 million people) 1 Seventh leading cause of death in the US 1
What is diabetes? DIABETES: Treatment and Management Steven Ferrucci, OD, FAAO Chief, Optometry, Sepulveda VA Professor, SCCO/MBKU DM is a chronic disorder characterized by a lack of insulin or increased
More informationSpeaker Disclosure Statement. " Dr. Tim Maillet and Dr. Vladimir Kozousek have no conflicts of interest to disclose.
Speaker Disclosure Statement Dr. Tim Maillet and Dr. Vladimir Kozousek have no conflicts of interest to disclose. Diabetes Morbidity Diabetes doubles the risk of stroke. Diabetes quadruples the risk of
More informationMolecular Biology of Diabetic Retinopathy
Opportunities for Therapeutic Intervention: Molecular Biology of Diabetic Retinopathy Jointly sponsored by The Dulaney Foundation and DIABETIC MICROVASCULAR COMPLICATIONS TODAY. Release Date: January 2006.
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time Version 4.0 July 21, 2017 peripheral dr lesions
More informationThe Foundation WHAT IS THE RETINA?
The Foundation American Society of Retina Specialists Committed to improving the quality of life of all people with retinal disease. Branch Retinal Vein Occlusion Retinal vein occlusions occur when there
More informationNew Insights on Treating Diabetic Retinopathy & Diabetic Macular Edema from the 2018 AAO Meeting
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCSME BCVA. OCT Bevacizumab CMT CMT BCVA. BCVA LogMAR. p CMT NPDR PDR PDR. Bevacizumab PDR FDA. Ranibizumab. Bevacizumab.
email: rezaj76@yahoo.com Bevacizumab FDA mg Ranibizumab - Bevacizumab NPDR PDR PDR PDR CSME FAZFA BCVA CMT OCT Bevacizumab BCVA CMT BCVA LogMAR p CMT p CSME CRVO CSME BRVO CRVOBRVO (fovea avascular zone)
More informationPROGRESSION OF DIABETIC RETINOPATHY FOLLOWING CATARACT SURGERY
PROGRESSION OF DIABETIC RETINOPATHY FOLLOWING CATARACT SURGERY Yayan Heryanto, Iwan Sovani, Arief Kartasasmita, Erwin Iskandar, Djonggi Panggabean. Dept. of Ophthalmology Medical Faculty Unpad, Cicendo
More informationManagement of diabetic eye disease: an overview
Peter Blows Photographic screening for diabetic eye disease can identify patients who will benefit from laser treatment. BOTSWANA MANAGEMENT Management of diabetic eye disease: an overview Laser for DR
More informationSlide notes: The major chronic complications of diabetes mellitus are described here. Among these, microvascular complications have an important
1 2 The major chronic complications of diabetes mellitus are described here. Among these, microvascular complications have an important role. They comprise microangiopathy, diabetic retinopathy, diabetic
More informationDiabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? WHAT CAUSES DIABETIC RETINOPATHY? WHAT ARE THE STAGES OF DIABETIC RETINOPATHY?
Diabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? Diabetic retinopathy affects 8 million Americans with diabetes. A leading cause of blindness in American adults, it is caused by damage to the small blood
More information